Wilmot Cancer Institute Appoints Karen Mustian as Associate Director for Population Science
Prominent Researcher Karen Mustian Advances in Cancer Research Leadership
Karen Mustian, a renowned researcher in the field of cancer survivorship, has been promoted to Associate Director of Population Science at Wilmot Cancer Institute, effective July 1, 2023. Mustian's expertise lies in the use of exercise and integrative medicine to alleviate the symptoms and side effects of cancer and its treatment.
Mustian's career at the University of Rochester Medical Center (URMC) began in 2003, where she joined as a research assistant professor. Over the years, she has risen through the ranks, demonstrating her commitment and impact in the field.
Mustian's contributions to cancer research are significant. She has been co-leader of Wilmot's Cancer Prevention and Control (CPC) research program and has played a crucial role in broadening its scope. Under her leadership, CPC has recruited new members engaged in cancer-prevention research in various areas. This expansion has been instrumental in increasing peer-reviewed funding for CPC by 67% since 2019, currently totalling $9.5 million.
Mustian's leadership in CPC has also been instrumental in securing substantial funding. In 2019, URMC received $29 million from NCORP, placing Wilmot at the hub of a national clinical trials research network. A staggering 87% of the funding for CPC under Mustian's leadership is from the National Cancer Institute.
Mustian's work in cancer survivorship has been influential in the development of exercise guidelines for cancer care and survivorship. She has conducted clinical trials demonstrating the benefits of physical activity and integrative strategies for reducing cancer-related fatigue and improving overall health outcomes among cancer survivors.
Mustian's influence extends beyond her local institution. She is a member of the NCI Board of Scientific Advisors and a national and international leader in her field, helping to craft American Society of Clinical Oncology guidelines for patient care.
However, for detailed and up-to-date information on her specific contributions and achievements, consulting authoritative sources such as her academic profile at her institution, published research articles, or professional society biographies would be necessary, as these are not captured in the current search results.
Mustian's achievements are not limited to her work in cancer research. In 2009, she founded and directed the PEAK human performance clinical research lab. She is also a principal investigator for an R01 award (Optimizing Functional Outcomes of Older Survivors after Chemotherapy).
Mustian will continue to oversee the CPC program in her new position as Associate Director of Population Science, ensuring that her impact in cancer research continues to grow and evolve.
- Karen Mustian, in her new role as Associate Director of Population Science, will continue to lead clinical trials focusing on alleviating symptoms and side effects of cancer and its treatment, contributing significantly to the science of cancer research.
- Mustian's influence in patient care extends beyond cancer treatment, as she has been instrumental in crafting American Society of Clinical Oncology guidelines and in the development of exercise guidelines for health-and-wellness, promoting fitness-and-exercise as crucial strategies for managing medical-conditions such as cancer.
- Mustian's research on cancer survivorship has demonstrated the benefits of physical activity and integrative strategies in reducing cancer-related fatigue and improving overall health outcomes, contributing to a broader understanding of health-and-wellness management in the context of various medical-conditions, including cancer.
